Less is more: once vs. multiple radioactive iodine (RAI) therapy in patients with RAI-avid pulmonary micrometastatic differentiated thyroid cancer.

Purpose: To date, the survival benefits of multiple radioactive iodine therapies (RAIT) in RAI-avid pulmonary micrometastatic differentiated thyroid cancer (DTC) remain debatable. This study aimed to compare the progression-free survival (PFS) benefits between those received only once RAIT (o-RAIT)...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 52; no. 13; pp. 4882 - 4893
Autores principales: Shi, Cong, Sun, Di, Sun, Yu-Qing, Zhang, Xin, Liu, Sheng-Yan, Li, Qi-Jun, Pan, Yi-Jin, Guo, Wen-Ting, Zhang, Ying-Qiang, Jin, Xiao-Na, Liu, Yu, Lin, Yan-Song
Formato: Journal Article
Publicado: Springer Nature Nov2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189136466&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 189136466
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Nov2025
      vid: 52
      iid: 13
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        189136466
        185384351
        10.1007/s00259-025-07339-3
        189136466
      ppf: 4882
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Less is more: once vs. multiple radioactive iodine (RAI) therapy in patients with RAI-avid pulmonary micrometastatic differentiated thyroid cancer.
      aug:
        au:
          Shi, Cong
          Sun, Di
          Sun, Yu-Qing
          Zhang, Xin
          Liu, Sheng-Yan
          Li, Qi-Jun
          Pan, Yi-Jin
          Guo, Wen-Ting
          Zhang, Ying-Qiang
          Jin, Xiao-Na
          Liu, Yu
          Lin, Yan-Song
        affil: https://ror.org/04jztag35 Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730, Beijing, China
      sug:
      ab: Purpose: To date, the survival benefits of multiple radioactive iodine therapies (RAIT) in RAI-avid pulmonary micrometastatic differentiated thyroid cancer (DTC) remain debatable. This study aimed to compare the progression-free survival (PFS) benefits between those received only once RAIT (o-RAIT) and multiple RAITs (m-RAIT) in such patients. Methods: Patients with RAI-avid pulmonary micrometastatic DTC were included and divided into either o-RAIT or m-RAIT group according to the number of RAIT cycles. The response to first RAIT in all patients and last RAIT in m-RAIT were evaluated and classified as partial response (PR), stable disease (SD), and progressive disease (PD). PFS was defined as the time from first RAIT to PD. Logistic regression analysis and Kaplan–Meier survival curves were employed to identify risk factors and estimate PFS, with propensity score matching (PSM) to reduce confounders. Results: A total of 117 patients with RAI-avid pulmonary micrometastatic DTC were retrospectively included, with 38 (32.5%) from o-RAIT and 79 (67.5%) from m-RAIT. Patients from m-RAIT exhibited younger age at diagnosis, more local persistent disease before RAIT, and more metachronous metastasis compared with o-RAIT group (all P < 0.05). In the comparison of RAIT response, there was no difference in the first RAIT response between the o-RAIT and m-RAIT, while the last RAIT response of m-RAIT is worse not only than o-RAIT (P = 0.005), but also than their own first RAIT response (P = 0.0003). Multivariate analysis revealed age at diagnosis (over 45 years old) (P = 0.006) and local persistent disease before RAIT (P = 0.001) were independent risk factors for PD after RAIT, while number of RAIT cycles was not. To minimize potential confounders, the risk factors for PD and follow-up time were matched by PSM, after which, no significant difference in PFS was observed between the matched o-RAIT and m-RAIT (5-year PFS rate: 83.6% vs. 81.6%, P = 0.808). Conclusions: In patients with RAI-avid pulmonary micrometastatic DTC, o-RAIT exhibited non-inferior PFS benefits compared with m-RAIT, suggesting the "less is more" management strategy of RAIT towards such patients.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N